#Icad results canada free

вЂњGBM is one of the deadliest of cancers and recurrence almost always occurs. вЂњThe interim results from this comparative study are very promising and the data adds to a growing body of research validating Xoft intraoperative radiation therapy (IORT) as an innovative treatment option for a variety of cancers, including recurrent GBM,вЂќ said Michael Klein, Chairman and CEO of iCAD. Patients treated with Xoft Brain IORT lived for a range of 4 to 54 months after treatment without recurrence, whereas patients in the control group had a recurrence within 2 to 10 months and lived for a range of 2 to 22.5 months after treatment. The median OS after re-resection was 11.0 months for the IORT group, versus 8.0 months for the control group the median locPFS for IORT was 8.0 months, versus 6.0 months for the control group.

#Icad results canada free

In the IORT group, as of March 2021, both the overall survival (OS) and local progression free survival (locPFS) continued to be superior to those in the control group. The comparative study evaluated 15 patients with recurrent GBM who were treated with maximal safe resection and Xoft intraoperative radiation therapy (IORT), and 15 patients treated with maximal safe resection and other modalities (control group), between June 2016 and June 2019. The study, titled вЂњRecurrent Glioblastoma Management with Maximal Safe Resection and Intraoperative Balloon Electronic Brachytherapy: Two Centers Study,вЂќ is under the guidance of lead investigator, Alexey Krivoshapkin, professor and head of the neurosurgery department at the European Medical Center (EMC) in Moscow, Russia. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that encouraging results from a prospective two center comparative study evaluating the XoftВ® AxxentВ® Electronic Brachytherapy (eBxВ®) SystemВ® for the treatment of recurrent glioblastoma (GBM), were presented at the American Association of Neurological Surgeons ( AANS) 2021 annual scientific meeting held virtually last week. Patients treated with Xoft Brain IORT lived for a range of 4 to 54 months after treatment without recurrence, whereas patients in the control group had a recurrence within 2 to 10 months and lived for 2 to 22.5 months after treatment